






[0015b] In a further aspect of the present disclosure, there is provided a compound, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, selected from the group consisting of:




























[0015c] In another aspect of the present disclosure, there is provided a compound, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, selected from the group consisting of:


















[0015d] In a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof disclosed herein, and a pharmaceutically acceptable excipient.

[0015e] In another aspect of the present disclosure, there is provided a compound, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof disclosed herein, for use in treating a TYK2-mediated disorder in a patient in need thereof, wherein the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

[0015f] In another aspect of the present disclosure, there is provided a use of a compound, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof disclosed herein, in the manufacture of a medicament for treating a TYK2-mediated disorder, wherein the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

[0016] Disclosed herein is a compound of Formula (XII), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:



Formula (XII),

wherein:

Ring B is cycloalkyl, heterocycloalkyl, aryl, heteroaryl;

R¹⁶ is -C(=O)NR¹R², -C(=N-CN)NR¹R², -P(=O)R¹R², or -C(=O)R¹¹;

R¹ and R² are independently hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, C₁-C₆aminoalkyl, C₂-C₆alkenyl, or C₂-C₆alkynyl;

R³ is hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, or C₁-C₆deuteroalkyl;

R⁴ is hydrogen, deuterium, halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -S(=O)₂R^a, -NO₂, -NR^cR^d, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, -P(=O)R^bR^b, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, C₁-C₆aminoalkyl, C₂-C₆alkenyl, or C₂-C₆alkynyl;

or R³ and R⁴ are taken together to form an optionally substituted ring;

L is a bond or -C(=O)-;

Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each optionally substituted with one or more R^A;

each R^A is independently deuterium, halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -S(=O)₂R^a, -NO₂, -NR^cR^d, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, C₁-C₆aminoalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆alkyl, or C₁-C₆haloalkyl;


or two R^A on the same carbon are taken together to form an oxo;

or -L-Ring A is absent;

CLAIMS


WHAT IS CLAIMED IS:

1. A compound of Formula (XII), or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof:



Formula (XII),

wherein:



Ring B is phenyl or a 5-10 membered heteroaryl;

R¹⁶ is -C(=O)R¹¹;

R³ is selected from the group consisting of hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, and C₁-C₆deuteroalkyl;

R⁴ is selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, -NR^bC(=O)R^a, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, and C₁-C₆aminoalkyl;

L is a bond;

Ring A is selected from the group consisting of heteroaryl and aryl; wherein Ring A is optionally substituted with one or more R^A;

each R^A is independently selected from the group consisting of deuterium, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, -NR^bC(=O)R^a, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, and C₁-C₆aminoalkyl; wherein each alkyl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆alkyl, or C₁-C₆haloalkyl;

each R^X is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, -NR^bC(=O)R^a, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, and C₁-C₆aminoalkyl;

R⁵ is selected from the group consisting of halogen, -CN, -OR⁸, -NR⁹R¹⁰, -NR⁸S(=O)R⁷, -NR⁸C(=N-CN)NR⁹R¹⁰, -NR⁸C(=O)NR⁹R¹⁰, -NR⁸C(=N-CN)R⁷, -NR⁸C(=N-OH)R⁷, NR⁸C(=O)R⁷, -NR⁸C(=N-CN)OR⁸, -NR⁸C(=O)OR⁸, -NR⁸S(=O)(=NR⁸)R⁷, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, C₁-C₆aminoalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, heterocycloalkyl, aryl, and heteroaryl; wherein each alkyl, alkenyl, alkynyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl,

C₁-C₆hydroxyalkyl, C₁-C₆aminoalkyl, C₁-C₆heteroalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆alkyl(cycloalkyl), C₁-C₆alkyl(heterocycloalkyl), C₁-C₆alkyl(aryl), or C₁-C₆alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆alkyl, or C₁-C₆haloalkyl;

R⁷ is independently selected from the group consisting of C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, C₁-C₆aminoalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

each R⁸ is independently selected from the group consisting of hydrogen, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, heterocycloalkyl, aryl, and heteroaryl; wherein each alkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

R⁹ and R¹⁰ are independently selected from the group consisting of hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, heterocycloalkyl, aryl, and heteroaryl; wherein each alkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, C₁-C₆deuteroalkyl, C₁-C₆haloalkyl, C₁-C₆hydroxyalkyl, C₁-C₆hydroxydeuteroalkyl, cycloalkyl, or heterocycloalkyl;

or R⁹ and R¹⁰ are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

or R⁸ and R⁹ are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

R¹¹ is selected from the group consisting of C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, C₁-C₆aminoalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, cycloalkyl, aryl, and heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R^{11a};

each R^{11a} is independently selected from the group consisting of deuterium, halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, and C₁-C₆aminoalkyl;

each R^a is independently selected from the group consisting of C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, and C₁-C₆hydroxyalkyl; wherein each alkyl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

each R^b is independently selected from the group consisting of hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, and C₁-C₆hydroxyalkyl; wherein each alkyl is independently optionally

substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

each R^c and R^d is independently selected from the group consisting of hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, and C₁-C₆hydroxyalkyl; wherein each alkyl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

Ring B is phenyl or pyridyl.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

Ring A is heteroaryl; wherein Ring A is optionally substituted with one or more R^A.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

Ring A is a 5-membered heteroaryl; wherein ring A is optionally substituted with one or more R^A.


5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

each R^A is independently selected from the group consisting of deuterium, halogen, C₁-C₆alkyl, C₁-C₆haloalkyl, and C₁-C₆deuteroalkyl.


6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

R⁴ is selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆alkyl, C₁-C₆haloalkyl, and C₁-C₆deuteroalkyl.

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein the compound is of formula (XIIa):



wherein:




R^3 is hydrogen; and

R^4 is hydrogen or $-OR^b$.

8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

R^{11} is selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 deuteroalkyl, C_1 - C_6 haloalkyl, and cycloalkyl.

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:



10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

R^5 is $NR^8C(=O)R^7$; wherein R^7 is cycloalkyl optionally substituted with one or more deuterium, halogen, $-CN$, $-OH$, $-OMe$, $-NH_2$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

R^5 is heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 deuteroalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 aminoalkyl, C_1 - C_6 heteroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(cycloalkyl), C_1 - C_6 alkyl(heterocycloalkyl), C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.


12. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

R^5 is $-NR^8C(=O)NR^9R^{10}$.


13. The compound of claim 12, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

R^9 and R^{10} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, $-CN$, $-OH$, $-OMe$, $-NH_2$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

14. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein the compound is represented by Formula (XIII):



wherein:



Ring B is phenyl or pyridyl;

R³ is selected from the group consisting of hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, and C₁-C₆deuteroalkyl;

R⁴ is selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆alkyl, C₁-C₆haloalkyl, and C₁-C₆deuteroalkyl;

L is a bond;

Ring A is a 5-membered heteroaryl may be substituted with one or more R^A;

each R^A is independently selected from the group consisting of deuterium, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, -NR^bC(=O)R^a, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, and C₁-C₆aminoalkyl; wherein each alkyl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆alkyl, or C₁-C₆haloalkyl;

R⁵ is -NR⁸C(=O)R⁷ or -NR⁸C(=O)NR⁹R¹⁰;

R⁷ is selected from the group consisting of C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, C₁-C₆aminoalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, and C₁-C₆haloalkyl;

each R⁸ is independently selected from the group consisting of hydrogen, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, heterocycloalkyl, aryl, and heteroaryl; wherein each alkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

R⁹ and R¹⁰ are independently selected from the group consisting of hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, heterocycloalkyl, aryl, and heteroaryl; wherein each alkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, C₁-C₆deuteroalkyl, C₁-C₆haloalkyl, C₁-C₆hydroxyalkyl, C₁-C₆hydroxydeuteroalkyl, cycloalkyl, and heterocycloalkyl;

or R⁹ and R¹⁰ are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

or R⁸ and R⁹ are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

R¹¹ is selected from the group consisting of C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, C₁-C₆aminoalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, cycloalkyl, aryl, and heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R^{11a};

each R^{11a} is independently selected from the group consisting of deuterium, halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, C₁-C₆hydroxyalkyl, and C₁-C₆aminoalkyl;

each R^a is independently selected from the group consisting of C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, and C₁-C₆hydroxyalkyl; wherein each alkyl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

each R^b is independently selected from the group consisting of hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, and C₁-C₆hydroxyalkyl; wherein each alkyl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

each R^c and R^d is independently selected from the group consisting of hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆deuteroalkyl, and C₁-C₆hydroxyalkyl; wherein each alkyl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, -C₁-C₆alkyl, or C₁-C₆haloalkyl.

15. The compound of claim 14, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:
each R^a is independently deuterium, halogen, C₁-C₆alkyl, C₁-C₆haloalkyl, or C₁-C₆deuteroalkyl.
16. The compound of claim 14 or 15, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:
R⁴ is hydrogen or -OR^b.
17. The compound of any one of claims 14-16, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:
R³ is hydrogen.
18. The compound of any one of claims 14-17, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

R¹¹ is C₁-C₆alkyl, C₁-C₆deuteroalkyl, C₁-C₆haloalkyl, or cycloalkyl.

19. The compound of any one of claims 14-18, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

R⁵ is -NR⁸C(=O)NR⁹R¹⁰.

20. The compound of claim 19, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:

R⁹ and R¹⁰ are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl.


21. The compound of any one of claims 14-18, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:


R⁵ is -NR⁸C(=O)R⁷.


22. The compound of any one of claims 14-18 or 21, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, wherein:


R⁷ is cycloalkyl optionally substituted with one or more deuterium, halogen, -CN, -OH, -OMe, -NH₂, C₁-C₆alkyl, or C₁-C₆haloalkyl.


23. A compound, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, selected from the group consisting of:















24. A compound, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, selected from the group consisting of:











25. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1-24, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, and a pharmaceutically acceptable excipient.
26. A compound of any one of claims 1-24, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, for use in treating a TYK2-mediated disorder in a patient in need thereof, wherein the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
27. Use of a compound of any one of claims 1-24, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, in the manufacture of a medicament for treating a TYK2-mediated disorder, wherein the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
28. The compound for use of claim 26, or the use of claim 27, wherein the disorder is selected from Crohn's disease, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, ulcerative colitis, and psoriatic arthritis.
29. The compound for use of claim 26, or the use of claim 27, wherein the disease or disorder is rheumatoid arthritis.
30. The compound for use of claim 26, or the use of claim 27, wherein the disease is psoriasis.
31. The compound for use of claim 26, or the use of claim 27, wherein the disease or disorder is systemic lupus erythematosus.
32. The compound for use of claim 26, or the use of claim 27, wherein the disease or disorder is ulcerative colitis.
33. The compound for use of claim 26, or the use of claim 27, wherein the disease or disorder is psoriatic arthritis.